BRIEF-Regenxbio Announces Additional Positive Long-Term And Interim Phase I/Iia Trial Update For Rgx-314 For The Treatment Of Wet AMD

简介-Regenxbio宣布,Rgx-314在治疗湿性AMD方面有更多的积极的长期和中期阶段I/IIa试验更新。

2020/04/22 18:33  Reuters

April 22 (Reuters) - Regenxbio Inc RGNX.O :

* REGENXBIO ANNOUNCES ADDITIONAL POSITIVE LONG-TERM AND INTERIM PHASE I/IIA TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD

* REGENXBIO INC - RGX-314 CONTINUES TO BE WELL-TOLERATED AT ALL DOSE LEVELS

* REGENXBIO INC - ON TRACK TO PROVIDE ONE-YEAR DATA FROM COHORTS 4 & 5 IN MID-2020 AND INITIATE RGX-314 SUBRETINAL DELIVERY PIVOTAL PROGRAM IN 2H 2020

* REGENXBIO INC - LONG-TERM, DURABLE TREATMENT EFFECT DEMONSTRATED OVER TWO YEARS IN COHORT 3 IN WET AMD TRIAL

* REGENXBIO INC - IN WET AMD TRIAL, 50% OF PATIENTS REMAIN ANTI-VEGF INJECTION-FREE OVER TWO YEARS

* REGENXBIO INC - IN WET AMD TRIAL, 67% OF PATIENTS ARE ANTI-VEGF INJECTION-FREE FROM NINE MONTHS TO TWO YEARS

Source text for Eikon: Further company coverage:

路透4月22日电-Regenxbio公司RGNX.O:

*REGENXBIO宣布RGX-314治疗湿性AMD的长期和中期I/IIA试验新进展。

*REGENXBIO公司-RGX-314继续在所有剂量水平上具有良好的耐受性。

*REGENXBIO公司将在2020年中期从第4和第5组提供一年数据,并在2H 2020启动RGX-314视网膜下分娩关键计划。

*REGENXBIO公司-长期、持久的治疗效果在第3组的湿式AMD试验中显示超过两年。

*Regenxbio公司-在湿式AMD试验中,50%的患者在两年内不注射抗VEGF药物。

*Regenxbio公司-在湿式AMD试验中,67%的患者在9个月至2年内不接受抗VEGF注射。

Eikon的原始文本:进一步的公司报道:

免责声明:中文翻译由腾讯翻译君提供支持,富途对翻译信息的准确性或可靠性所造成的任何损失不承担任何责任。

Copyright©2019 FUTU. All rights reserved. FUTU does not provide any investment advice.